Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 4/20 | 0.62 |
| ▸ | SRD5A1 | P18405 | 7/20 | 0.56 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.56 |
| ▸ | FNTA | P49354 | 4/20 | 0.56 |
| ▸ | FNTB | P49356 | 4/20 | 0.56 |
| ▸ | USP2 | O75604 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3042515 | 1.00 | NPC1L1 (0.62) | NPC1L1SRD5A1SRD5A2FNTAFNTB | |
| SCHEMBL3042519 | 1.00 | NPC1L1 (0.62) | NPC1L1SRD5A1SRD5A2FNTAFNTB | |
| SCHEMBL6389282 | 0.89 | NPC1L1 (0.58) | NPC1L1FNTAFNTB | |
| SCHEMBL6389278 | 0.89 | NPC1L1 (0.58) | NPC1L1FNTAFNTB | |
| SCHEMBL2637542 | 0.83 | NPC1L1 (0.66) | NPC1L1SRD5A1SRD5A2FNTAFNTB | |
| SCHEMBL2637544 | 0.83 | NPC1L1 (0.66) | NPC1L1SRD5A1SRD5A2FNTAFNTB | |
| SCHEMBL3824442 | 0.81 | NPC1L1 (0.72) | NPC1L1SRD5A1SRD5A2FNTAFNTB | |
| SCHEMBL6393696 | 0.81 | NPC1L1 (0.72) | NPC1L1SRD5A1SRD5A2FNTAFNTB | |
| SCHEMBL6388577 | 0.81 | NPC1L1 (0.72) | NPC1L1SRD5A1SRD5A2FNTAFNTB | |
| SCHEMBL17817392 | 0.81 | NPC1L1 (0.72) | NPC1L1SRD5A1SRD5A2FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575138-B2 | Method for providing neuroprotection | TROPHOS (FR) | 2013-11-05 | — | — | US | disclosed |
| US-8354395-B2 | Method for providing neuroprotection from spinal muscular atrophy | TROPHOS (FR) | 2013-01-15 | — | — | US | disclosed |
| US-20120316141-A1 | METHOD FOR PROVIDING NEUROPROTECTION FROM SPINAL MUSCULAR ATROPHY | TROPHOS (FR) | 2012-12-13 | — | — | US | disclosed |
| US-20120309721-A1 | METHOD FOR PROVIDING NEUROPROTECTION | TROPHOS (FR) | 2012-12-06 | — | — | US | disclosed |
| US-8283341-B2 | Use as medicaments of derivatives of cholest-4-en-3-one, pharmaceutical compositions containing them, novel derivatives and their preparation process | TROPHOS (FR) | 2012-10-09 | — | — | US | disclosed |
| EP-1601363-B1 | USE OF DERIVATIVES OF CHOLEST-4-EN-3-ONE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, NOVEL DERIVATIVES AND PREPARATION METHOD THEREOF | TROPHOS (FR) | 2012-06-20 | — | — | EP | disclosed |
| US-7858603-B2 | neuroprotectants such as 1,4-cholestadien-3-one oxime, used for the treatment of neurodegenerative diseases | TROPHOS (FR) | 2010-12-28 | — | — | US | disclosed |
| US-20100216752-A1 | USE AS MEDICAMENTS OF DERIVATIVES OF CHOLEST-4-EN-3-ONE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, NOVEL DERIVATIVES AND THEIR PREPARATION PROCESS | TROPHOS (FR) | 2010-08-26 | — | — | US | disclosed |
| US-20060217358-A1 | Use of derivatives of cholest-4-en-3-one as medicaments, pharmaceutical compositions containing same, novel derivatives and preparation method thereof | TROPHOS (FR) | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216752-A1 | USE AS MEDICAMENTS OF DERIVATIVES OF CHOLEST-4-EN-3-ONE, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, NOVEL DERIVATIVES AND THEIR PREPARATION PROCESS | CYP27A1, NLN, NPC1 | NPC1L1 25/4885SRD5A1 485/4885SRD5A2 407/4885 |
| US-20120309721-A1 | METHOD FOR PROVIDING NEUROPROTECTION | BDNF, NLN, DCX | NPC1L1 1941/4885SRD5A1 1477/4885SRD5A2 1357/4885 |
| US-20120316141-A1 | METHOD FOR PROVIDING NEUROPROTECTION FROM SPINAL MUSCULAR ATROPHY | SMN1; SMN2, BDNF, SOD1 | NPC1L1 3403/4885SRD5A1 1935/4885SRD5A2 1894/4885 |
| US-20060217358-A1 | Use of derivatives of cholest-4-en-3-one as medicaments, pharmaceutical compositions containing same, novel derivatives and preparation method thereof | CYP46A1, NR1H4, CYP27A1 | NPC1L1 28/4885SRD5A1 34/4885SRD5A2 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.